These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


408 related items for PubMed ID: 25467252

  • 1. Management of post-transplant Epstein-Barr virus-related lymphoproliferative disease in solid organ and hematopoietic stem cell recipients.
    Marques HH, Shikanai-Yasuda MA, dAzevedo LS, Caiaffa-Filho HH, Pierrotti LC, Aquino MZ, Lopes MH, Maluf NZ, Campos SV, Costa SF.
    Rev Soc Bras Med Trop; 2014; 47(5):543-6. PubMed ID: 25467252
    [Abstract] [Full Text] [Related]

  • 2. Prospective Epstein-Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment.
    Chiereghin A, Prete A, Belotti T, Gibertoni D, Piccirilli G, Gabrielli L, Pession A, Lazzarotto T.
    Transpl Infect Dis; 2016 Feb; 18(1):44-54. PubMed ID: 26574232
    [Abstract] [Full Text] [Related]

  • 3. Epstein-Barr virus-related post-transplant lymphoproliferative disorder in solid organ transplant recipients.
    San-Juan R, Comoli P, Caillard S, Moulin B, Hirsch HH, Meylan P, ESCMID Study Group of Infection in Compromised Hosts.
    Clin Microbiol Infect; 2014 Sep; 20 Suppl 7():109-18. PubMed ID: 24475976
    [Abstract] [Full Text] [Related]

  • 4. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases.
    Styczynski J, Einsele H, Gil L, Ljungman P.
    Transpl Infect Dis; 2009 Oct; 11(5):383-92. PubMed ID: 19558376
    [Abstract] [Full Text] [Related]

  • 5. The value of EBV DNA in early detection of post-transplant lymphoproliferative disorders among solid organ and hematopoietic stem cell transplant recipients.
    Wareham NE, Mocroft A, Sengeløv H, Da Cunha-Bang C, Gustafsson F, Heilmann C, Iversen M, Kirkby NS, Rasmussen A, Sørensen SS, Lundgren JD, MATCH in PERSIMUNE study group.
    J Cancer Res Clin Oncol; 2018 Aug; 144(8):1569-1580. PubMed ID: 29804164
    [Abstract] [Full Text] [Related]

  • 6. Comparative analysis of post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation reveals differences in the tumor microenvironment.
    Overkamp M, Granai M, Bonzheim I, Steinhilber J, Schittenhelm J, Bethge W, Quintanilla-Martinez L, Fend F, Federmann B.
    Virchows Arch; 2021 Jun; 478(6):1135-1148. PubMed ID: 33324999
    [Abstract] [Full Text] [Related]

  • 7. Management of post-transplant lymphoproliferative disorders.
    Llaurador G, McLaughlin L, Wistinghausen B.
    Curr Opin Pediatr; 2017 Feb; 29(1):34-40. PubMed ID: 27906865
    [Abstract] [Full Text] [Related]

  • 8. Current preventive strategies and management of Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH Questionnaire-based Cross-sectional Survey.
    San-Juan R, Manuel O, Hirsch HH, Fernández-Ruiz M, López-Medrano F, Comoli P, Caillard S, Grossi P, Aguado JM, ESGICH PTLD Survey Study Group,, European Study Group of Infections in Compromised Hosts (ESGICH) from the European Society of Microbiology and Infectious Diseases (ESCMID).
    Clin Microbiol Infect; 2015 Jun; 21(6):604.e1-9. PubMed ID: 25686696
    [Abstract] [Full Text] [Related]

  • 9. The management of Epstein-Barr virus associated post-transplant lymphoproliferative disorders in pediatric solid-organ transplant recipients.
    Green M, Michaels MG, Webber SA, Rowe D, Reyes J.
    Pediatr Transplant; 1999 Nov; 3(4):271-81. PubMed ID: 10562971
    [Abstract] [Full Text] [Related]

  • 10. Identifying predictive factors for posttransplant lymphoproliferative disease in pediatric solid organ transplant recipients with Epstein-Barr virus viremia.
    Weintraub L, Weiner C, Miloh T, Tomaino J, Joashi U, Benchimol C, Strauchen J, Roth M, Wistinghausen B.
    J Pediatr Hematol Oncol; 2014 Nov; 36(8):e481-6. PubMed ID: 24878618
    [Abstract] [Full Text] [Related]

  • 11. Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies.
    Gao XN, Lin J, Wang LJ, Li F, Li HH, Wang SH, Huang WR, Gao CJ, Yu L, Liu DH.
    Ann Hematol; 2019 Sep; 98(9):2163-2177. PubMed ID: 31243569
    [Abstract] [Full Text] [Related]

  • 12. Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation.
    Romero S, Montoro J, Guinot M, Almenar L, Andreu R, Balaguer A, Beneyto I, Espí J, Gómez-Codina J, Iacoboni G, Jarque I, López-Andújar R, Mayordomo-Aranda E, Montalar J, Pastor A, Pastor M, Piñana JL, Rojas-Ferrer N, Sánchez-Lázaro I, Sandoval J, Sanz G, Sanz MÁ, Solé A, Sanz J.
    Leuk Lymphoma; 2019 Jan; 60(1):142-150. PubMed ID: 29966464
    [Abstract] [Full Text] [Related]

  • 13. [Prophylaxis against Epstein Barr disease in pediatric and adult patients undergoing solid organ and hematopoietic stem cells transplantation].
    Catalán P, Alba A.
    Rev Chilena Infectol; 2012 Sep; 29 Suppl 1():S29-31. PubMed ID: 23282553
    [Abstract] [Full Text] [Related]

  • 14. The role of quantitative Epstein-Barr virus polymerase chain reaction and preemptive immunosuppression reduction in pediatric liver transplantation: a preliminary experience.
    Kogan-Liberman D, Burroughs M, Emre S, Moscona A, Shneider BL.
    J Pediatr Gastroenterol Nutr; 2001 Oct; 33(4):445-9. PubMed ID: 11698761
    [Abstract] [Full Text] [Related]

  • 15. [Latest update on immunotherapy of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease].
    Hao QF, Sheng GY, Luan Z.
    Zhongguo Dang Dai Er Ke Za Zhi; 2013 Sep; 15(9):795-9. PubMed ID: 24034931
    [Abstract] [Full Text] [Related]

  • 16. The Changing Epidemiology of Posttransplant Lymphoproliferative Disorder in Adult Solid Organ Transplant Recipients Over 30 Years: A Single-center Experience.
    Peters AC, Akinwumi MS, Cervera C, Mabilangan C, Ghosh S, Lai R, Iafolla M, Doucette K, Preiksaitis JK.
    Transplantation; 2018 Sep; 102(9):1553-1562. PubMed ID: 29485513
    [Abstract] [Full Text] [Related]

  • 17. The Immune Response to Epstein Barr Virus and Implications for Posttransplant Lymphoproliferative Disorder.
    Martinez OM, Krams SM.
    Transplantation; 2017 Sep; 101(9):2009-2016. PubMed ID: 28376031
    [Abstract] [Full Text] [Related]

  • 18. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
    Styczynski J, Gil L, Tridello G, Ljungman P, Donnelly JP, van der Velden W, Omar H, Martino R, Halkes C, Faraci M, Theunissen K, Kalwak K, Hubacek P, Sica S, Nozzoli C, Fagioli F, Matthes S, Diaz MA, Migliavacca M, Balduzzi A, Tomaszewska A, Camara Rde L, van Biezen A, Hoek J, Iacobelli S, Einsele H, Cesaro S, Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
    Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985
    [Abstract] [Full Text] [Related]

  • 19. Management of Epstein-Barr virus-induced post-transplant lymphoproliferative disease in recipients of solid organ transplantation.
    Green M.
    Am J Transplant; 2001 Jul; 1(2):103-8. PubMed ID: 12099356
    [Abstract] [Full Text] [Related]

  • 20. Host microRNAs are decreased in pediatric solid-organ transplant recipients during EBV+ Post-transplant Lymphoproliferative Disorder.
    Sen A, Enriquez J, Rao M, Glass M, Balachandran Y, Syed S, Twist CJ, Weinberg K, Boyd SD, Bernstein D, Trickey AW, Gratzinger D, Tan B, Lapasaran MG, Robien MA, Brown M, Armstrong B, Desai D, Mazariegos G, Chin C, Fishbein TM, Venick RS, Tekin A, Zimmermann H, Trappe RU, Anagnostopoulos I, Esquivel CO, Martinez OM, Krams SM.
    Front Immunol; 2022 Jul; 13():994552. PubMed ID: 36304469
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 21.